Trial Profile
Clinical trial of WT1 and MUC1 peptide-pulsed dendritic cell vaccine for post-operative patients with pancreatic cancer or biliary cancer
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 16 Feb 2021
Price :
$35
*
At a glance
- Drugs Tumour peptide-loaded dendritic cell vaccine Tella (Primary)
- Indications Biliary cancer; Pancreatic cancer
- Focus Adverse reactions
- Sponsors Tella
- 15 Feb 2021 Status changed from recruiting to completed.
- 09 Apr 2013 New trial record